Akèy › Kasinom Selil Transizyonèl (Urotelyal) › Kalifòni
Etid klinik pou Kasinom Selil Transizyonèl (Urotelyal) nan Kalifòni
33 etid pou Kasinom Selil Transizyonèl (Urotelyal) ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
- Los Angeles17 etid
- Orange10 etid
- Baldwin Park9 etid
- Irvine8 etid
- San Francisco7 etid
- Santa Monica6 etid
- San Diego5 etid
- Santa Barbara4 etid
- Torrance3 etid
- Newport Beach3 etid
Tèks ofisyèl etid la (Anglè)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #59, Santa Barbara
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06524544A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- City of Hope National Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- Ronald Reagan UCLA Medical Center, Los Angeles
- ak 3 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Samsun Clinic - Ridley-Tree Cancer Center, Santa Barbara
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07566156Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Providence St. Johns Health Center, Santa Monica
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05874921A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045), Orange
- University of California San Francisco ( Site 1044), San Francisco
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05562830Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- UCLA Hematology/Oncology - Alhambra, Alhambra
- UCLA Hematology/Oncology - Atascadero, Atascadero
- UCLA Hematology/Oncology - Beverly Hills, Beverly Hills
- ak 39 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- City of Hope Cancer Center-Duarte, Duarte
- Providence Medical Foundation, Santa Rosa
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07277413Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Precision NextGen Oncology, Beverly Hills
- OPN Healthcare, Inc, Glendale
- University of Southern California, Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine
- TRIO-US (Translational Research in Oncology-US), Los Angeles
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
- ak 4 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06439836A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
- Research Site, Los Angeles
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07815665Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- City of Hope, Duarte
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- Michael G Oefelein Clinical Trials, Bakersfield
- UC Irvine Health. Chao Family Comprehensive Cancer Center, Orange
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06774131Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06582017Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Los Angeles
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07129993A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Community Cancer Institute, Clovis
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT04895709A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Los Angeles Cancer Network, Los Angeles
- Pih Health Hematology Medical Oncology, Whittier
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07628634Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- City of Hope, Duarte
- Los Angeles Cancer Network, Glendale
- California Research Institute, Los Angeles
- ak 3 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, San Francisco
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Kaiser Permanente Anaheim Kraemer Medical Offices, Anaheim
- Foothill Cardioology, Arcadia
- Kaiser Permanente Baldwin Park Medical Center, Baldwin Park
- ak 58 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT04879329A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- USC Norris Comprehensive Cancer Center, Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT07169734Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Urology Associates of Central California, Fresno
- Urology Group of Southern California, Los Angeles
- Comprehensive Urology, Los Angeles
Ap rekrite
Laj 18 a 88 · Tout sèks · Mizajou Jul 2, 2026 · NCT06394869Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
- University of California, Davis, Sacramento
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06101290Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
- City of Hope, Duarte
- COH Lennar, Irvine
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT07484022Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT06682728A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Dec 11, 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- ak 3 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Southern California, Los Angeles
- University of California, San Francisco, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT05107674Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
- Sarcoma Oncology Center, Santa Monica
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 3, 2025 · NCT06493552A Multicenter Cancer Biospecimen Collection Study
- Curebase, San Francisco
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 12, 2025 · NCT04510129Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.